
Mika Hori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5009714/publications.pdf Version: 2024-02-01



MIKA HORI

#	Article	IF	CITATIONS
1	Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma. Clinical and Translational Gastroenterology, 2014, 5, e53.	2.5	126
2	Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans. Cancer Science, 2018, 109, 3013-3023.	3.9	78
3	Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 181-188.	2.4	77
4	Homozygous Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2021, 28, 665-678.	2.0	55
5	Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E41-E49.	3.6	51
6	Suppression of mutagenesis by 8-hydroxy-2′-deoxyguanosine 5′-triphosphate (7,8-dihydro-8-oxo-2′-deoxyguanosine 5′-triphosphate) by human MTH1, MTH2, and NUDT5. Free Radical Biology and Medicine, 2010, 48, 1197-1201.	2.9	50
7	Diagnosis and Management of Sitosterolemia 2021. Journal of Atherosclerosis and Thrombosis, 2021, 28, 791-801.	2.0	50
8	Involvement of specialized DNA polymerases in mutagenesis by 8-hydroxy-dGTP in human cells. DNA Repair, 2009, 8, 637-642.	2.8	39
9	Enhancement of Carcinogenesis and Fatty Infiltration in the Pancreas in N-Nitrosobis(2-Oxopropyl)Amine-Treated Hamsters by High-Fat Diet. Pancreas, 2011, 40, 1234-1240.	1.1	39
10	Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 547-555.e5.	1.5	39
11	Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients. Atherosclerosis, 2019, 289, 101-108.	0.8	37
12	Achilles Tendon Ultrasonography for Diagnosis of Familial Hypercholesterolemia Among Japanese Subjects. Circulation Journal, 2017, 81, 1879-1885.	1.6	32
13	Experimental Animal Models of Pancreatic Carcinogenesis for Prevention Studies and Their Relevance to Human Disease. Cancers, 2011, 3, 582-602.	3.7	30
14	Dual hydrolysis of diphosphate and triphosphate derivatives of oxidized deoxyadenosine by Orf17 (NtpA), a MutT-type enzyme. DNA Repair, 2005, 4, 33-39.	2.8	27
15	Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments. Journal of Atherosclerosis and Thrombosis, 2021, 28, 905-925.	2.0	27
16	NUDT5 hydrolyzes oxidized deoxyribonucleoside diphosphates with broad substrate specificity. DNA Repair, 2009, 8, 1250-1254.	2.8	24
17	Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis. Carcinogenesis, 2020, 41, 490-501.	2.8	21
18	Current Diagnosis and Management of Abetalipoproteinemia. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1009-1019.	2.0	21

Mika Hori

#	Article	IF	CITATIONS
19	A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 346-351.e9.	1.5	20
20	Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. Journal of Atherosclerosis and Thrombosis, 2022, 29, 816-824.	2.0	20
21	The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580ÂG>A: p.(Arg3527Gln). Journal of Clinical Lipidology, 2020, 14, 482-486.	1.5	18
22	Evaluation of the degree of pancreatic fatty infiltration by area-based assessment of CT images: comparison with histopathology-based and CT attenuation index-based assessments. Japanese Journal of Radiology, 2016, 34, 667-676.	2.4	17
23	Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. Journal of Clinical Lipidology, 2018, 12, 62-69.e1.	1.5	17
24	Patients With <i>LDLR</i> and <i>PCSK9</i> Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia. Journal of the American Heart Association, 2021, 10, e018263.	3.7	15
25	Current Diagnosis and Management of Primary Chylomicronemia. Journal of Atherosclerosis and Thrombosis, 2021, 28, 883-904.	2.0	14
26	In Vivo Mutagenicities of Damaged Nucleotides Produced by Nitric Oxide and Ionizing Radiation. Biological and Pharmaceutical Bulletin, 2005, 28, 520-522.	1.4	12
27	UvrA and UvrB enhance mutations induced by oxidized deoxyribonucleotides. DNA Repair, 2007, 6, 1786-1793.	2.8	12
28	Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 413-421.e3.	1.5	12
29	Effects of Overexpression and Antisense RNA Expression of Orf17, a MutT-Type Enzyme. Biological and Pharmaceutical Bulletin, 2006, 29, 1087-1091.	1.4	10
30	Mutagenicity of secondary oxidation products of 8-oxo-7,8-dihydro-2′-deoxyguanosine 5′-triphosphate (8-hydroxy-2′- deoxyguanosine 5′-triphosphate). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 714, 11-16.	1.0	9
31	Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1603-1612.	2.0	9
32	Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy. Journal of the American Heart Association, 2021, 10, e019525.	3.7	8
33	Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an <i>LDL Receptor</i> Mutation and a <i>PCSK9</i> V4I Mutation. Internal Medicine, 2018, 57, 3551-3557.	0.7	7
34	Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society. JACC Asia, 2021, 1, 245-255.	1.5	7
35	Current Status of Familial LCAT Deficiency in Japan. Journal of Atherosclerosis and Thrombosis, 2021, 28, 679-691.	2.0	6
36	A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the <i>PCSK9</i> and <i>ABCG5</i> Genes and Type I CD36 Deficiency. Journal of Atherosclerosis and Thrombosis, 2022, 29, 551-557.	2.0	5

Mika Hori

#	Article	IF	CITATIONS
37	High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides. Nutrients, 2022, 14, 975.	4.1	5
38	Invasive Ductal Carcinoma Developing in Pancreas With Severe Fatty Infiltration. Pancreas, 2012, 41, 1137-1139.	1.1	3
39	Detection of the benign c.2579C>T (p.A860V) variant of the LDLR gene in a pedigree-based genetic analysis of familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 335-339.	1.5	3
40	Achilles Tendon Softness as a New Tool for Diagnosing Familial Hypercholesterolemia. JACC: Cardiovascular Imaging, 2021, 14, 1483-1485.	5.3	3
41	Circulating Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 Concentration Predicts Future Coronary Events in Japanese Subjects. JACC Asia, 2021, , .	1.5	3
42	Discontinuation of LDL apheresis with evolocumab in an FH patient with a duplication of exon 2–6 in the LDLR gene. Journal of Cardiology Cases, 2019, 19, 55-58.	0.5	2
43	The benign c.344G > A: p.(Arg115His) variant in the LDLR gene interpreted from a pedigree-based genetic analysis of familial hypercholesterolemia. Lipids in Health and Disease, 2020, 19, 62.	3.0	2
44	No enhancing effects of plasmid-specific histone acetyltransferase recruitment system on transgene expression in vivo. Nucleosides, Nucleotides and Nucleic Acids, 2019, 38, 942-949.	1.1	1
45	Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion. CEN Case Reports, 2021, 10, 592-597.	0.9	1
46	Acute Cholesterol-Lowering Effect of Exendin-4 in <i>Ldlr</i> ^{â^'/â^'} and C57BL/6J Mice. Journal of Atherosclerosis and Thrombosis, 2023, 30, 74-86.	2.0	1
47	Can We Clarify the Causative Gene/Variants Underlying Familial Hypercholesterolemia and Improve Genetic Diagnosis Rate?. Journal of Atherosclerosis and Thrombosis, 2021, , .	2.0	0
48	Identification of a novel large duplication (exon2_6dup): copy number variation in the LDLR gene in a large family with familial hypercholesterolemia by whole-genome sequencing. Journal of Clinical Lipidology, 2022, , .	1.5	0